公开(公告)号：US20240041968A1

公开(公告)日：2024-02-08

申请号：US18486306

申请日：2023-10-13

Applicant: GOLO LLC

Inventor： Christopher Brian LUNDIN ,  Terry Shirvani

IPC: A61K36/73 ,  A61K36/41 ,  A23L33/00 ,  A61K33/06 ,  A61P3/00 ,  A61K33/30 ,  A61K36/37 ,  A61K36/185 ,  A61K36/744

CPC classification number: A61K36/73 ,  A61K36/41 ,  A23L33/30 ,  A61K33/06 ,  A61P3/00 ,  A61K33/30 ,  A61K36/37 ,  A61K36/185 ,  A61K36/744

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

公开(公告)号：US20220347252A1

公开(公告)日：2022-11-03

申请号：US17812068

申请日：2022-07-12

Applicant: GOLO LLC

Inventor： Christopher Brian LUNDIN ,  Terry SHIRVANI

IPC: A61K36/73 ,  A61K36/41 ,  A23L33/00 ,  A61K33/06 ,  A61P3/00 ,  A61K33/30 ,  A61K36/37 ,  A61K36/185 ,  A61K36/744

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

公开(公告)号：US11484514B2

公开(公告)日：2022-11-01

申请号：US16957432

申请日：2018-12-20

Applicant: NUBEBE CO., LTD. ,  HUMAN HERB CO., LTD.

Inventor： Young Woo Lim ,  Ji Myeong Ok ,  Woon Ho Lee ,  Young Bin Kim

IPC: A61P3/04 ,  A61K36/346 ,  A61K36/488 ,  A61K36/882 ,  A61K36/49 ,  A61K36/8994 ,  A61K36/31 ,  A61K36/736 ,  A61K36/8945 ,  A61K36/185 ,  A61K47/02 ,  A61K47/46 ,  A61K36/534 ,  A61K36/744 ,  A61K36/538 ,  A61K36/708 ,  A61K33/04 ,  A61K36/64 ,  A61K36/65 ,  A61K31/137 ,  A61K9/19 ,  A61K36/258 ,  A61K36/481 ,  A61K36/284 ,  A61K36/54 ,  A61K36/9068 ,  A61K36/076 ,  A61K36/752 ,  A61K36/725 ,  A61K36/734 ,  A61K36/575 ,  A61K36/884 ,  A61J3/06 ,  A61K9/28 ,  A61K36/17 ,  A61K36/62

Abstract: An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which is prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated ephedra powder agent so that an ephedrine content is 3.0-4.0%; determining a weight of the concentrated ephedra powder agent according to each constitution of Sasang constitutional medicine, and manufacturing a side effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the concentrated ephedra powder agent; mixing the concentrated ephedra powder agent and the side effect-preventing powder agent with a variance of a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects; and tableting the mixture of the prepared ephedra powder agent and side effect-preventing powder agent.

公开(公告)号：US20220202889A1

公开(公告)日：2022-06-30

申请号：US17560772

申请日：2021-12-23

Applicant: Liwei Sun

Inventor： Liwei Sun ,  Rui Jiang ,  Daqing Zhao ,  Xiaohao Xu ,  Xuenan Chen ,  Jianzeng Liu ,  Rui Ma

IPC: A61K36/258 ,  A61K36/725 ,  A61K36/074 ,  A61K36/076 ,  A61K36/14 ,  A61K36/79 ,  A61K36/8967 ,  A61K36/48 ,  A61K36/287 ,  A61K36/484 ,  A61K36/896 ,  A61K36/744 ,  A61K36/254 ,  A61P25/20

Abstract: The present disclosure belongs to the technical field of health care products or foods and provides the use of a ginseng alcohol extract in sleep-promoting health care products or foods. Through analysis utilizing DAM2 drosophila behavior monitoring system, it is found that the ginseng alcohol extract can increase total sleep duration of normal and sleep deprived drosophilae, and relieve sleep rhythm disorder caused by sleep deprivation. Through a climbing experiment, it is found that the ginseng alcohol extract can improve the climbing ability of normal and sleep deprived drosophilae. The ginseng alcohol extract, on the one hand, improves the quality of sleep to protect the steady state of sleep rhythm, and on the other hand, increases the motive ability after sleep. The ginseng alcohol extract of the present disclosure is intended to be used to sleep-promoting health care products or healthy foods and improve the quality of sleep.

公开(公告)号：US20220062364A1

公开(公告)日：2022-03-03

申请号：US17010883

申请日：2020-09-03

Applicant: Chen-Yu LEE

Inventor： Hsuan-Ching TSENG ,  Da-Tong JU ,  Sung-Sen YANG ,  Wei-Te CHENG ,  Chen-Yu LEE ,  Yan-Chih LIAO

IPC: A61K36/515 ,  A61K36/539 ,  A61K36/744 ,  A61K36/232 ,  A61K36/64 ,  A61K36/71 ,  A61K36/233 ,  A61K36/68 ,  A61K36/284 ,  A61K36/884 ,  A61K36/484 ,  A61K36/899 ,  A61K36/65 ,  A61K36/488 ,  A61K36/708 ,  A61K36/734 ,  A61K35/57 ,  A61P13/10 ,  A61P13/02 ,  A61P25/00 ,  A61P1/14

Abstract: The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising gentiana scabra, scutellariae Radix, gardeniae fructus, angelicae sinensis Radix, rehmanniae radix, akebiae caulis, Bupleurum chinense, plantaginis Semen, Atractylodes lancea, rhizoma alismatis, and glycyrrhiza uralensis.

公开(公告)号：US20210023157A1

公开(公告)日：2021-01-28

申请号：US16519033

申请日：2019-07-23

Applicant: Enliven Biotechnology Co.,Ltd.

Inventor： Jaan-Yih TSAI ,  Lin-Yu TSAI ,  Yih-Chih TSAI

IPC: A61K36/236 ,  A61K36/708 ,  A61K36/232 ,  A61K36/539 ,  A61K36/718 ,  A61K36/744 ,  A61K36/258 ,  A61K36/79 ,  A61K36/282 ,  A61K36/355 ,  A61K36/898 ,  A61K9/19 ,  A61P25/00

Abstract: The present invention provides a method for treating brain stroke, including: administering to a subject in need a composition, including: an extract of a mixture, wherein the mixture includes Chuanxiong Rhizoma, Rhei Radix et Rhizoma, Angelicae Dahuricae Radix, Scutellaria baicalensis, Coptidis Rhizoma, Gardeniae Fructus, and Carica papaya.

公开(公告)号：US10851129B2

公开(公告)日：2020-12-01

申请号：US16097247

申请日：2017-03-16

Applicant: Jinan University

Inventor： Xinsheng Yao ,  Dan Zhang ,  Yang Yu ,  Xiuqi Bao ,  Yang Ni ,  Caixia Zang

IPC: A61K31/7016 ,  C07H13/06 ,  A61K31/7024 ,  A61K36/744 ,  A23L33/105 ,  C07H13/04 ,  A61P25/28

Abstract: A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-β-D-gentiobioside, crocetin-β-D-glucopyranosyl-β-D-gentiobioside, crocetin di-β-D-glucopyranoside, 13Z-crocetin di-β-D-gentiobioside, neocrocin B, crocetin mono-β-D-gentiobioside, 13Z-crocetin-8-O-β-D-gentiobioside, 13Z-crocetin-8′-O-β-D-gentiobioside, and crocetin mono-β-D-glucopyranoside. Pharmacological experiment results show that the crocins active site can effectively improve learning and memory injuries in mice induced by scopolamine and amyloid β protein.

公开(公告)号：US20200323941A1

公开(公告)日：2020-10-15

申请号：US16956460

申请日：2018-12-20

Applicant: VT CM Pty Ltd

Inventor： Vivian TAM

IPC: A61K36/756 ,  A61K9/00 ,  A61K9/20 ,  A61K36/86 ,  A61K36/65 ,  A61K36/744 ,  A61K36/537 ,  A61K36/515 ,  A61K36/288 ,  A61K36/355 ,  A61K36/73 ,  A61K36/9068 ,  A61K36/484 ,  A61K36/534

Abstract: There is disclosed a clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of the Chinese medicinal composition comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia suffruticosa and gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5-5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica/Rhizoma Coptidas/Sophora flavescens.

公开(公告)号：US20200164017A1

公开(公告)日：2020-05-28

申请号：US16777534

申请日：2020-01-30

Applicant: Yoshiteru SHIMOIDE

Inventor： Yoshiteru SHIMOIDE

IPC: A61K36/718 ,  A61K36/756 ,  A61K36/539 ,  A61K36/744 ,  A61K36/488 ,  A61K36/54 ,  A61K36/484 ,  A61K36/284 ,  A61K36/076 ,  A61P13/12 ,  A61P13/10 ,  A61P1/10 ,  A61P25/28

Abstract: Provided is a kampo medicine for treating multimorbidity of Alzheimer-type dementia or mild cognitive impairment and at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney disease with one drug. A kampo medicine for treating multimorbidity with one drug, comprising a drug combination of orengedokuto and ryokeijutsukanto as an active ingredient, wherein the kampo medicine improves a cognitive function in Alzheimer-type dementia or mild cognitive impairment and relieves and treats at least one disease from overactive bladder, constipation, and chronic kidney disease complicated by Alzheimer-type dementia or mild cognitive impairment at a high rate with one drug.

公开(公告)号：US10660929B2

公开(公告)日：2020-05-26

申请号：US16210343

申请日：2018-12-05

Applicant: Yoshiteru Shimoide

Inventor： Yoshiteru Shimoide

IPC: A61K36/00 ,  A61K36/718 ,  A61P25/28 ,  A61P1/10 ,  A61P13/10 ,  A61P13/12 ,  A61K36/076 ,  A61K36/284 ,  A61K36/484 ,  A61K36/54 ,  A61K36/488 ,  A61K36/744 ,  A61K36/539 ,  A61K36/756

Abstract: Provided is a kampo medicine for treating multimorbidity of Alzheimer-type dementia or mild cognitive impairment and at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney disease with one drug. A kampo medicine for treating multimorbidity with one drug, comprising a drug combination of orengedokuto and ryokeijutsukanto as an active ingredient, wherein the kampo medicine improves a cognitive function in Alzheimer-type dementia or mild cognitive impairment and relieves and treats at least one disease from overactive bladder, constipation, and chronic kidney disease complicated by Alzheimer-type dementia or mild cognitive impairment at a high rate with one drug.